Guido Oelkers, Sobi CEO

As­traZeneca nix­es $8B So­bi buy­out over fears a for­mer drug would be sold to ri­vals — re­port

As­traZeneca has re­port­ed­ly tanked a deal that would have tak­en high-pro­file rare dis­ease com­pa­ny So­bi pri­vate over fears its res­pi­ra­to­ry drugs would fall in­to the hands of ri­vals.

The Big Phar­ma with­held its 8% stake in So­bi af­ter a $7.6 bil­lion of­fer from Ad­vent In­ter­na­tion­al and Sin­ga­pore’s sov­er­eign wealth fund closed in Sep­tem­ber, Bloomberg re­port­ed ear­ly Fri­day morn­ing, ef­fec­tive­ly block­ing the buy­out. So­bi, al­so known as Swedish Or­phan Biovit­rum, pos­sessed cer­tain as­sets As­traZeneca it­self was in­ter­est­ed in ac­quir­ing, the re­port said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.